» Articles » PMID: 17490724

The Invasive Front in Endometrial Carcinoma: Higher Proliferation and Associated Derailment of Cell Cycle Regulators

Overview
Journal Hum Pathol
Specialty Pathology
Date 2007 May 11
PMID 17490724
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the study was to explore whether expression of proliferation and hypoxia-related proteins differs in the central parts and the invasive front in endometrial carcinomas. Proliferation-associated proteins Ki67 and cyclin A; cell cycle regulators p16, p21, p53, cyclin D1, cyclin E, and cdk2; and hypoxia-inducible factor 1alpha and its downstream factors glucose transporter 1, carbonic anhydrase IX, and vascular endothelial growth factor were immunohistochemically stained in paraffin-embedded specimens from endometrioid (n = 33), mucinous (n = 1), and serous (n = 5) endometrial carcinomas. The percentages of positive cells at the invasive front and central tumor parts were scored and compared. Ki67 (P < .001), cyclin E (P = .018), p16 (P = .003), and cdk2 (.001) were expressed higher at the invasive front than centrally (Wilcoxon signed ranks test). Higher expression of these antigens at the invasive front was seen in 31 of 38 cases for Ki67, in 16 of 39 cases for cyclin E, in 15 of 39 cases for cdk2, and in 11 of 39 cases for p16. The other cell cycle proteins and the hypoxia-related factors did not show significant differences in expression between the central parts and the invasive front. Endometrial carcinomas clearly show an invasive front that is characterized by higher proliferation and progressive derailment of the cell cycle regulators cyclin E, p16, and cdk2, but not by an increased hypoxic response.

Citing Articles

Notch and Hedgehog Signaling Unveiled: Crosstalk, Roles, and Breakthroughs in Cancer Stem Cell Research.

Iluta S, Nistor M, Buruiana S, Dima D Life (Basel). 2025; 15(2).

PMID: 40003637 PMC: 11856057. DOI: 10.3390/life15020228.


The usefulness of p16 and COX-2 expression on the prediction of progression to endometrial cancer.

Kalkan H, Akman L, Serin G, Terek M, Zekioglu O, Ozsaran A Histol Histopathol. 2023; 39(5):565-571.

PMID: 37503793 DOI: 10.14670/HH-18-650.


Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer.

Fan X, Xie F, Zhang L, Tong C, Zhang Z Front Mol Biosci. 2022; 9:961450.

PMID: 36060256 PMC: 9428456. DOI: 10.3389/fmolb.2022.961450.


Role of Precision Oncology in Type II Endometrial and Prostate Cancers in the African Population: Global Cancer Genomics Disparities.

Marima R, Hull R, Mbeje M, Molefi T, Mathabe K, Elbagory A Int J Mol Sci. 2022; 23(2).

PMID: 35054814 PMC: 8776204. DOI: 10.3390/ijms23020628.


Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma.

Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares A, Jacome M Front Cell Dev Biol. 2021; 9:670185.

PMID: 34150764 PMC: 8209546. DOI: 10.3389/fcell.2021.670185.